Deep-dive analysis on biotech deal trends, competitive landscapes, and investment opportunities.
Analysis of 389 licensing deals across therapeutic areas, modalities, and development stages.
Complete competitive landscape with $18.5B+ in committed capital across 9 clinical-stage assets.
23 assets in development with $28B+ in total deal value. Phase 3 data readouts expected 2026.
Which therapeutic areas are attracting acquisition interest and at what valuations.